1. Hoffman AA: LSD: My Problem Child. Los Angeles, JP Tarcher, 1983.
2. Johnston LD, O'Malley PM, Bachman JG (eds): National Survey Results from the Monitoring the Future Study, 1975-1995. Washington, DC, U.S. Department of Health and Human Services, 1996.
3. Cuomo MJ, Dyment PG, Gammino VM: Increasing use of "ecstasy" (MDMA) and other hallucinogens on a college campus. J Am Coll Health 42:271, 1994
4. Substance Abuse and Mental Health Administration: Year End Preliminary Estimates from the 1996 Drug Abuse Warning Network (DAWN). Washington, DC, US Department of Health and Human Services, 1997.
5. Glennon RA: Do hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology 3:509, 1990.
6. Klock JC, Boerner U, Becker CE: Coma, hyperthermia, and bleeding associated with massive LSD overdose: a report of eight cases. Clin Toxicol 8:191, 1975.
7. Abraham HD, Aldridge AM: Adverse consequences of lysergic acid diethylamide. Addiction 88:1327, 1993.
8. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994.
9. Renfroe CL, Messinger TA: Street drug analysis: An eleven year perspective on illicit drug alteration. Semin Adolesc Med 1:247, 1985.
10. Davis M: Mescaline: Excitatory effects on acoustic startle are blocked by serotonin 2 antagonists. Psychopharmacology 93:286, 1987.
11. Johnson MP, Hoffman AJ, Nichols DE: Effects of the enantiomers of MDA, MDMA, and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269, 1986.
12. Dowling GP, McDonough ET, Bost RO: 'Eve' and 'ecstasy': A report of five deaths associated with the use of MDEA and MDMA. JAMA 257:1615, 1987.
13. Henry JA, Jeffreys KJ, Dawling S: Toxicity and deaths from 3,4 methylenedioxymethamphetamine ("ecstasy"). Lancet 340:384, 1992.
14. Mueller PD, Korey WS: Death by "ecstasy": the serotonin syndrome? Ann Emerg Med 32:377, 1998.
15. McCann UD, Rideroun A, Shaham Y, et al: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946, 1992.
16. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301, 1991.
17. McCaron MM, Schulze BW, Thompson GA, et al: Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med 10:237, 1981.
18. McCarron MM, Schulze BW, Thompson GA, et al: Acute phencyclidine intoxication: clinical patterns, complications, and treatment. Ann Emerg Med 10:290, 1981.
19. Simpson GM, Khajawall AM, Alatorre E et al: Urinary phencyclidine excretion in chronic abusers. J Toxicol Clin Toxicol 19:1051, 1982.
20. Devane WA, Hanus L, Breuer A, et al: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946, 1992.
21. Dackis CA, Pottash ALC, Annitto W, et al: Persistence of urinary marijuana levels after supervised abstinence. Am J Psychiatry 139:1196, 1982.
Was this article helpful?
If you're wanting to learn about drug addiction... Then this may be the most important letter you'll ever read You Are Going To Get A In Depth Look At One Of The Most Noteworthy Guides On Drug Addiction There Is Available On The Market Today. It Doesn't Matter If You Are Just For The First Time Looking For Answers On Drug Addiction, This Guide Will Get You On The Right Track.